Production (Stage)
Acrivon Therapeutics, Inc.
ACRV
$1.17
$0.021.74%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -30.62% | -33.40% | -53.75% | -54.03% | -74.69% |
| Total Depreciation and Amortization | 72.13% | 87.69% | 66.41% | 48.28% | 43.02% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 17.09% | 26.12% | 40.21% | 102.54% | 179.70% |
| Change in Net Operating Assets | -49.43% | -70.04% | 113.11% | 63.09% | 1,049.30% |
| Cash from Operations | -40.84% | -54.00% | -53.11% | -46.26% | -46.32% |
| Capital Expenditure | 3.22% | -114.91% | -696.91% | -158.35% | -17.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -173.80% | -194.23% | 34.02% | 47.57% | 137.89% |
| Cash from Investing | -181.30% | -202.08% | 29.65% | 46.07% | 135.81% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 8,097.78% | 8,943.48% | -32.89% | -32.78% | -99.18% |
| Repurchase of Common Stock | -84.42% | -94.29% | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 4,893.64% | 5,280.23% | 2,118.01% | 2,009.30% | 59.72% |
| Cash from Financing | 7,102.09% | 7,888.10% | 16.95% | 18.75% | -101.70% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 602.21% | -45.00% | 706.96% | 117.36% | 95.49% |